Role of 5α-reductase inhibitors in prostate cancer prevention and treatment

Urology

Volumn 79, Issue 6, 2012, Pages 1197-1205

  Azzouni, Faris ^a   Mohler, James ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CHOLESTEROL; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; HYDROCORTISONE; IZONSTERIDE; KETOCONAZOLE; PLACEBO; PREGNANEDIONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL FAILURE FREE SURVIVAL; BREAST AUGMENTATION; BREAST TENDERNESS; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GASTROINTESTINAL DISEASE; GLEASON SCORE; GYNECOMASTIA; HEART FAILURE; HORMONE SYNTHESIS; HUMAN; LIBIDO DISORDER; LIVER FUNCTION TEST; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL FUNCTION; SIDE EFFECT; TERATOGENICITY; TUMOR BIOPSY;

5-ALPHA REDUCTASE INHIBITORS; ANDROGEN ANTAGONISTS; AZASTEROIDS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FINASTERIDE; HUMANS; MALE; PRIMARY PREVENTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861744513     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.01.024     Document Type: Review

References (65)

1. G. Aumüller, W. Eicheler, H. Renneberg Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues Acta Anat (Basel) 156 1996 241 252
2. V. Cantagrel, D.J. Lefeber, B.G. Ng SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder Cell 142 2010 203 217
3. A. Godoy, E. Kawinski, Y. Li 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression Prostate 71 10 2011 1033 1046
4. L.N. Thomas, R.C. Douglas, C.B. Lazier Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer J Urol 179 2008 147 151 (Pubitemid 350216746)
5. L.N. Thomas, C.B. Lazier, R. Gupta Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer Prostate 63 2005 231 239 (Pubitemid 40571057)
6. D.C. Miller, M.G. Sanda, R.L. Dunn Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy J Clin Oncol 23 12 2005 2772 2780 (Pubitemid 46179467)
7. W.A. Sakr, D.J. Grignon, J.D. Crissman High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases In Vivo 8 1994 439 443
8. P.W. Swindle, M.W. Kattan, P.T. Scardino Markers and meaning of primary treatment failure Urol Clin North Am 30 2003 377 401 (Pubitemid 36520609)
9. I.M. Thompson, P.J. Goodman, C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224 (Pubitemid 36859473)
10. G.L. Andriole, D.G. Bostwick, O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
11. G.L. Andriole, C. Roehrborn, C. Schulman Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia Urology 64 2004 537 541
12. G. Andriole, M. Bautista, D. Crawford Prostate cancer (CAP) detection in the medical therapy of prostatic symptoms (MTOPS) trial J Urol 169 suppl 2003 120
13. G.L. Andriole, H.A. Guess, J.I. Epstein Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial PLESS Study Group. Proscar long-term efficacy and safety study Urology 52 1998 195 201
14. GlaxoSmithKline Advisory Committee Briefing Document Avodart for the reduction of risk of prostate cancer. Oncology Drugs Advisory Committee http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/OncologicDrugsAdvisoryCommittee/UCM234936.pdf Accessed February 28, 2012
15. M.R. Cooperberg, J.M. Broering, P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
16. R. Rittmaster, F. Montorsi, M. Marberger Reduction in surgical and non-surgical interventions for prostate cancer with dutasteride treatment in the reduction by dutasteride of prostate cancer events (REDUCE) study Eur Soc Med Oncol 2010 Milan
17. I.M. Thompson, C. Chi, D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133 (Pubitemid 44288787)
18. I.M. Thompson, C.M. Tangen, P.J. Goodman Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection J Urol 177 2007 1749 1752 (Pubitemid 46560657)
19. J.B. Basillote, N.A. Armenakas, D.A. Hochberg Influence of prostate volume in the detection of prostate cancer Urology 61 2003 167 171 (Pubitemid 36151735)
20. R. Serfling, M. Shulman, G.L. Thompson Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling J Urol 177 2007 2352 2356 (Pubitemid 46726388)
21. M.S. Lucia, J.I. Epstein, P.J. Goodman Finasteride and high-grade prostate cancer in the prostate cancer prevention trial J Natl Cancer Inst 99 2007 1375 1383 (Pubitemid 351767184)
22. Y.C. Cohen, K.S. Liu, N.L. Heyden Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the prostate cancer prevention trial J Natl Cancer Inst 99 2007 1366 1374 (Pubitemid 351767189)
23. G. Andriole, R.S. Rittmaster Dutasteride and prostate cancer [letter to the editor] N Engl J Med 363 2010 794 795
24. R. Choo, C. Danjoux, G. Morton How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 67 2007 1614 1620 (Pubitemid 350036947)
25. C.G. Roehrborn, P. Siami, J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
26. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. In press.
27. J.D. McConnell, R. Bruskewitz, P. Walsh The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 338 1998 557 563 (Pubitemid 28114643)
28. C.G. Roehrborn, P. Boyle, J.C. Nickel Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2002 434 441 (Pubitemid 35292169)
29. N.M. Makridakis, R.K. Ross, M.C. Pike Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA Lancet 354 9183 1999 975 978 (Pubitemid 29438402)
30. P.C. Walsh Effect of dutasteride on the risk of prostate cancer [Editorial] J Urol 194 2010 174 175
31. Walsh PC. Re: The prostate cancer prevention trial: design, biases and interpretation of study results. Goodman P, Thompson I, Tangen C, et al. J Urol. 2006;175:2234-2242. J Urol. 2006;176:2744.
32. T.J. Murtola, T.L. Tammela, L. Määttänen Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish prostate cancer screening trial Br J Cancer 101 2009 843 848
33. R.S. Svatek, J.J. Lee, C.G. Roehrborn Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis Cancer 112 2008 1058 1065 (Pubitemid 351304590)
34. O. Cussenot, A.R. Azzouzi, N. Nicolaiew Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors Eur Urol 52 2007 1082 1089 (Pubitemid 47337033)
35. C.L. Pearce, N.M. Makridakis, R.K. Ross Steroid 5-alpha reductase type II V89L gene substitution is not associated with risk of prostate cancer in a multiethnic population study Cancer Epidemiol Biomarkers Prev 11 4 2002 417 418 (Pubitemid 34408223)
36. R.K. Nam, A. Toi, D. Vesprini V89L polymorphism of type-2, 5-alpha-reductase enzyme gene predicts prostate cancer presence and progression Urology 57 1 2001 199-105
37. B. Kramer, K. Hagerty, S. Justman Use of 5α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline J Urol 181 2009 1642 1657
38. F. Civantos, R.B. Watson, J.E. Pinto Finasteride effect on benign prostatic hyperplasia and prostate cancer: a comparative clinico-pathologic study of radical prostatectomies J Urol Pathol 6 1997 1 8
39. X.J. Yang, K. Lecksell, K. Short Proscar Long-Term Efficacy and Safety Study Group Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study Urology 53 1999 696 700 (Pubitemid 29163032)
40. R. Bass, B. Perry, P. Langenstroer Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells J Urol 181 2009 615 620
41. G.L. Andriole, P. Humphrey, P. Ray Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer J Urol 172 2004 915 919 (Pubitemid 39096422)
42. K.A. Iczkowski, J. Qiu, J. Qian The dual 5alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate Urology 65 2005 76 82 (Pubitemid 40169609)
43. M. Gleave, J. Qian, C. Andreou The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer - results from a 4-month pre-radical prostatectomy study Prostate 66 2006 1674 1685 (Pubitemid 44646358)
44. A. Staack, A.P. Kassis, A. Olshen Quantitation of apoptotic activity following castration in human prostatic tissue in vivo Prostate 54 3 2003 212 219 (Pubitemid 36120319)
45. N. Ohlson, P. Wikström, P. Stattin Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment Prostate 62 4 2005 307 315 (Pubitemid 40224136)
46. A.B. Barqawi, J.W. Moul, A. Ziada Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy Urology 62 2003 872 876 (Pubitemid 37421234)
47. L.L. Bañez, G.W. Blake, D.G. McLeod Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up BJU Int 104 2009 310 314
48. W.K. Oh, J. Manola, L. Bittmann Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up Urology 62 2003 99 104 (Pubitemid 36802080)
49. G. Andriole, M. Lieber, J. smith Treatment with finasteride following radical prostatectomy for prostate cancer Urology 45 3 1995 491 497
50. M. Perotti, R. Jain, L. Abriel Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study Urol Oncol Semin Orig Inves 2010 [Epub ahead of print]
51. N. Sato, M.E. Gleave, N. Bruchovsky Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model J Steroid Biochem Mol Biol 58 2 1996 139 146 (Pubitemid 26284510)
52. F.E. Calais da Silva, A.V. Bono, P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
53. L. Klotz, C. O'Callaghan, K. Ding A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK intercontinental trial CRUKE/01/013 JCO 29 suppl 2011 3
54. S.E. Eggener, J.A. Stern, P.M. Jain Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model Prostate 66 5 2006 495 502
55. Y. Wang, S. Gupta, V. Hua Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model Prostate 70 2010 147 154
56. M.C. Scholz, R.I. Jennrich, S.B. Strum Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period J Urol 175 5 2006 1673 1678
57. J.A. Locke, N. Bruchovsky Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy Can J Urol 17 3 2010 5162 5169
58. J.L. Mohler, C.W. Gregory, O.H. Ford 3rd The androgen axis in recurrent prostate cancer Clin Cancer Res 10 2004 440 448 (Pubitemid 38173980)
59. M.A. Titus, M.J. Schell, F.B. Lih Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 2005 4653 4657 (Pubitemid 41557182)
60. M. Stanbrough, G.J. Bubley, K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
61. J.A. Locke, E.S. Guns, A.A. Lubik Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
62. M.A. Eisenberger, M. Laufer, N.J. Vogelzang Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action Urology 63 2004 114 119 (Pubitemid 38147562)
63. S. Shah, D. Trump, O. Sartor Phase II study of dutasteride in recurrent prostate cancer during androgen-deprivation therapy J Uro 181 2009 621 626
64. O. Sartor, M. Nakabayashi, M.E. Taplin Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone Clin Genitourin Cancer 7 3 2009 E90 E92
65. M.E. Taplin, M.M. Regan, Y.J. Ko Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer Clin Cancer Res 15 22 2009 7099 7105